Company news

Sab Biotherapeutics, Inc. (NASDAQ:SABS) news

Sab Biotherapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research…

Sab Biotherapeutics, Inc. (NASDAQ:SABS) news

Press releases & updates

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

SAB BIO Highlights Data in Multiple Presentations at EASD

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

SAB BIO Reports Full Year 2024 Operating and Financial Results

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Appoints Lucy To as Chief Financial Officer

SAb Biotherapeutics Rebrands as SAB BIO

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

SAB Biotherapeutics Announces Departure of Chief Financial Officer

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results